# Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea

> **NCT06998095** · — · NOT_YET_RECRUITING · sponsor: **AstraZeneca** · enrollment: 210 (estimated)

## Conditions studied

- Severe Asthma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06998095
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11-28
- **Primary completion:** 2029-10-31
- **Final completion:** 2029-10-31
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06998095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06998095, "Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06998095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*